Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
703 (USA) · Dr. Okafor
consented 2013-03-02
AEs
2
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Mild DIARRHOEA — outcome: RECOVERED/RESOLVED; onset 2013-03-04 (study day 3.0); relationship: POSSIBLE
mild
assessed
Mild INSOMNIA — outcome: RECOVERED/RESOLVED; onset 2013-03-05 (study day 4.0); relationship: REMOTE
Data queries
No data queries.